|
|
 |
 |
| |
 Printable version |
mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma |
Bulletin du Cancer. Volume 97, 45-51, Cancers du rein, Synthèse
|
 Résumé
Article gratuit
|
Author(s) : A Ravaud, J-C Bernhard, M Gross-Goupil, L Digue, J-M Ferriere |
Summary : mTOR signaling pathway (mammalian target of rapamycin) is a major pathway in cell physiology and malignant behavior implicated in cell growth, cell proliferation, cell metabolism, protein synthesis and angiogenesis. Temsirolimus has shown in a randomized phase III trial for patients with poor risk feature of metastatic renal cell carcinoma, a significant gain in overall survival compared to this obtained with alpha interferon (7.3 à 10.9 months\; HR: 0.73\; P <\; 0.0069). Everolimus has shown in a randomized phase III trial for patients with metastatic renal cell carcinoma having failed under VEGFR tyrosine kinase inhibitor a significant gain in progression-free survival compared to this obtained with placebo VEGFR (1,8 à 4,6 months\; HR: 0.33\; P <\; 0.001). Temsirolimus and everolimus are now part of the reference treatments in renal cell carcinoma. This paper is a review of these two drugs in this setting. |
Keywords : mTOR inhibitor, renal cell carcinoma, temsirolimus, everolimus |
|
